Header Logo

Connection

Kai Ding to Clinical Trials, Phase I as Topic

Back to Details
This is a "connection" page, showing publications Kai Ding has written about Clinical Trials, Phase I as Topic.
Kai Ding
Connection Strength
0.037
Clinical Trials, Phase I as Topic
  1. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.